The Mesoblast (ASX:MSB) share price surges on award win

The Mesoblast Limited (ASX: MSB) share price surged higher today after winning an industry award. Here’s why the biotech company is one to watch

| More on:
row of piggy banks with large one receiving injection representing rising Immutep share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast Limited (ASX: MSB) share price has jumped today on the back of winning the Fierce Innovation Award. The Mesoblast share price was trading at $4.95, up 6.6% from yesterday’s market close. It has since dropped back to $4.85 at the time of writing, up 4.53%.

This compares to the S&P/ASX 200 Index (ASX: XJO) which is down 0.1% at 5,892 points.

Winner of 2020 biotech innovation

Mesoblast announced that its flagship product remestemcel-L had won the Fierce Innovation Awards: Life Sciences Edition 2020 for biotech innovation. The evaluation criteria for these awards is based on effectiveness, technical innovation, competitive advantage, financial impact, and true innovation.

The peer-reviewed program is overseen by a panel of executives from major biotech and pharmaceutical companies. They include Astellas, Accenture, AstraZeneca, Angiocrine Bioscience, Biotech Research Group, NIHR Clinical Research Network, Medidata Solutions and PPD.

Mesoblast chief executive Dr Silviu Itescu was proud of the company’s achievements, saying the award was an important recognition of the Mesoblast’s efforts. Mr Itescu said the company strived for innovation in the cell therapy industry and sought to help children suffering from preventable diseases.

What is remestemcel-L

Mesoblast’s lead drug candidate remestemcel-L is a cellular therapy product that comprises cultured, cryopreserved mesenchymal stem cells derived from the bone marrow of healthy donors.

The company is developing remestemcel-L to treat steroid-refractory acute graft versus host disease (SR-aGVHD). Mesoblast has also been experimenting with the product to treat patients infected with COVID-19.

Hero drug updates

Remestemcel-L is currently under priority review by the United States Food and Drug Administration (FDA) awaiting approval. It is anticipated the product will launch in the US at the end of 2020. The FDA will convene on September 30 to decide on whether remestemcel-L’s will receive its new drug approval stamp.

In addition, Mesoblast plans to gauge remestemcel-L’s effectiveness on 300 ventilator-dependant adults with COVID-19 in a controlled Phase III trial. The company will seek to confirm results from a pilot study at New York’s Mt Sinai hospital which showed a 75% recovery rate after 10 days of receiving two intravenous doses of remestemcel-L.

Should you invest in the Mesoblast share price?

Mesoblast shares have soared higher since COVID-19 swept the world. The Mesoblast share price is up 348% in the last 6 months and could continue to go higher if the FDA approves Mesoblast’s hero drug. It will be interesting to watch the ongoing developments in the coming weeks. I urge investors to pay close attention. The Mesoblast share is one to add to your watchlist.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A man and a woman sit in front of a laptop looking fascinated and captivated.
Share Market News

Here are the top 10 ASX 200 shares today

Tuesday was a particularly good day for these 10 ASX 200 shares.

Read more »

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin.

Can the Bitcoin price reach US$30,000 again in 2022?

Rising interest rates have resulted in significantly less institutional investor interest in cryptos.

Read more »

An office worker and his desk covered in yellow post-it notes
Share Market News

Here are the 3 most heavily traded ASX 200 shares on Tuesday

Once again, its ASX 200 lithium stocks that are dominating today;s volume charts.

Read more »

A woman shouts through a megaphone.
Share Market News

In this most volatile of years, the ASX 200 is within shouting distance of turning positive

ASX 200 continues its recovery, now within shouting distance of turning positive for 2022.

Read more »

A man in his 30s holds his computer underneath and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
Financial Shares

Are AMP shareholders heading for a $1 billion pay day?

AMP shareholders could benefit from buybacks following the successful divestment of AMP’s Collimate Capital business.

Read more »

Smiling man with phone in wheelchair watching stocks and trends on computer
Share Market News

5 things to watch on the ASX 200 on Tuesday

Here's what to expect on the ASX 200 on Tuesday...

Read more »

Businessman cheering at desk with arms in the air
Share Market News

Here are the top 10 ASX 200 shares today

These ten ASX 200 shares outperformed all others on Monday.

Read more »

A man wearing a suit holds his arms aloft with a smile on his face is attached to a large lithium battery with green charging symbols on it.
Share Market News

Here are the 3 most heavily traded ASX 200 shares on Monday

It's all about that lithium for the most traded ASX 200 shares today.

Read more »